Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire's goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. The most advanced compounds in Inspire's clinical pipeline are denufosol tetrasodium for cystic fibrosis and PROLACRIA(TM) (diquafosol tetrasodium ophthalmic solution) 2% for dry eye, which are both in Phase 3 development, and AZASITE(R) (azithromycin ophthalmic solution) 1% for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye.
Company Details
- Founded
- -
- in****@****arm.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- inspirepharm.com
- Keywords
- Inspire Medical Systems.
Inspire Questions
Inspire's website is inspirepharm.com
Inspire's LinkedIn profile is https://www.linkedin.com/company/inspire
Inspire's industry is
Pharmaceutical Manufacturing
Inspire's top competitors are
Inspire,
Niox®,
Shire,
Inspire,
Muro Pharmaceuticals, Inc.,
Kpmg Nederland,
Sanofi,
Inspire,
Parion Sciences,
Inspire Medical Systems.
Inspire's support email address is info@inspirepharm.com
Inspire's categories are Pharmaceutical Manufacturing
Inspire's founding year is 1995
